For more information, contact our Communications Office at 225-763-2750 or email email@example.com with your questions or comments.
Pennington Biomedical Researchers to Examine if Vitamin D Prevents DiabetesReleased: Monday, October 21, 2013
BATON ROUGE, LA - Pennington Biomedical Research Center announced today that it is recruiting volunteers to take part in the first definitive, large-scale clinical trial to investigate if a vitamin D supplement helps prevent or delay type 2 diabetes in adults who have prediabetes, who are at high risk for type 2. Funded by the National Institutes of Health, the study is taking place at about 20 study sites across the United States.
The multiyear Vitamin D and Type 2 Diabetes (D2d) study will include about 2,500 people. Its goal is to learn if vitamin D - specifically D3 (cholecalciferol) - will prevent or delay type 2 diabetes in adults aged 30 or older with prediabetes. People with prediabetes have blood glucose levels that are higher than normal but not high enough to be called diabetes.
"Pennington Biomedical is pleased to be one of the institutions selected for this important national study," said George Bray, M.D., Boyd Professor and principal investigator for D2d at Pennington Biomedical Research Center. "People who are at risk for developing diabetes and enter this clinical trial will have the opportunity to participate in a forward-looking study that will try to prevent this disease from developing. It is an exciting study, and we encourage anyone interested in volunteering to contact the Pennington Biomedical Recruiting Department," added Dr. Bray.
"This study aims to definitively answer the question: Can vitamin D reduce the risk of developing type 2 diabetes?" said Myrlene Staten, M.D., D2d project officer at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of NIH. "Vitamin D use has risen sharply in the U.S. in the last 15 years, since it has been suggested as a remedy for a variety of conditions, including prevention of type 2 diabetes. But we need rigorous testing to determine if vitamin D will help prevent diabetes. That's what D2d will do."
"Past observational studies have suggested that higher levels of vitamin D may be beneficial in preventing type 2 diabetes, but until this large, randomized and controlled clinical trial is complete, we won't know if taking vitamin D supplements lowers the risk of diabetes," said Anastassios G. Pittas, M.D., the study's principal investigator at Tufts Medical Center, Boston.
D2d is the first study to directly examine if a daily dose of 4,000 International Units (IUs) of vitamin D - greater than a typical adult intake of 600-800 IUs a day, but within limits deemed appropriate for clinical research by the Institute of Medicine - helps keep people with prediabetes from getting type 2 diabetes. Based on observations from earlier studies, researchers speculate that vitamin D could reduce the diabetes risk by 25 percent. The study will also examine if sex, age or race affect the potential of vitamin D to reduce diabetes risk.
"An estimated 79 million Americans have prediabetes, and nearly 26 million more have diabetes," said NIDDK Director Griffin P. Rodgers, M.D. "With D2d, we seek evidence for an affordable and accessible way to help prevent or delay type 2 diabetes."
Researchers are recruiting volunteers to take part in D2d. Half of the participants will receive vitamin D. The other half will receive a placebo - a pill that has no drug effect. Participants will have check-ups for the study twice a year, and will receive regular health care through their own health care providers.
The study will be double-blinded, so neither participants nor the study's clinical staff will know who is receiving vitamin D and who is receiving placebo. The study will continue until enough people have developed type 2 diabetes to be able to make a scientifically valid comparison between diabetes development in the two groups, likely about four years.
D2d builds on previous NIH-funded studies of methods to delay or prevent type 2 diabetes, including the Diabetes Prevention Program, which showed that, separately, lifestyle changes to lose a modest amount of weight and the drug metformin are both effective in slowing development of type 2 diabetes in people with prediabetes. However, additional safe and effective preventative strategies are needed to stem the increasing numbers of people developing type 2 diabetes.
D2d (ClinicalTrials.gov number NCT01942694) is supported under NIH grant U01DK098245. The NIDDK is the primary sponsor of the trial, with additional support from the NIH Office of Dietary Supplements and the American Diabetes Association. Support in the form of educational materials is provided by the National Diabetes Education Program.
The Pennington Biomedical Research Center is at the forefront of medical discovery as it relates to understanding the triggers of obesity, diabetes, cardiovascular disease, cancer and dementia. It is a campus of Louisiana State University and conducts basic, clinical and population research. The research enterprise at Pennington Biomedical includes approximately 80 faculty and more than 25 post-doctoral fellows who comprise a network of 44 laboratories supported by lab technicians, nurses, dietitians, and support personnel, and 13 highly specialized core service facilities. Pennington Biomedical’s more than 500 employees perform research activities in state-of-the-art facilities on the 222-acre campus located in Baton Rouge, Louisiana.